Krystal Biotech, Inc. · NASDAQ:KRYS
Krystal Biotech — Q4 2023 Earnings Presentation
15 slides from Krystal Biotech's earnings presentation, Feb 26, 2024
Slide 1: Fourth Quarter and Full Year 2023 Financial Results and Business Update
Fourth Quarter and Full Year 2023 Financial Results and Business Update February 26, 2024 © Copyright 2024 Krystal Biotech, Inc. All rights reserved.
Slide 2: Forward Looking Statements and Disclosures
Forward Looking Statements and Disclosures Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about future expectations, plans and prospects for Krystal Biotech, Inc. (together with or
Slide 3: 2023 Was a Breakthrough Year for Krystal
2023 Was a Breakthrough Year for Krystal ▪ Received FDA approval for VYJUVEK®, the first and only corrective therapy for DEB ▪ Strong U.S. launch underway with $50.7M in net product revenue in only two quarters since approval ▪ Significant progress and expansion of clinical pipeline with 5 active cl
Slide 4: Over $50M in Product Net Revenue in First Months Post Approval
Over $50M in Product Net Revenue in First 6 Months Post Approval VYJUVEK U.S. Net Revenue ($M) ▪ Gross margins of 93% in Q4 $42.1 ▪ Gross-to-net adjustments in Q4 were 14% ▪ Transient impact from J-code | Price cap accruals $8.6 Q3 2023 Q4 2023 Krystal | 4
Slide 5: Significant Revenue Growth Opportunities Outside of the United States
Significant Revenue Growth Opportunities Outside of the United States Thousands Estimated ROW DEB Pts $1B+ Global VYJUVEK 500+ Market Opportunity 2,900+ Estimated Japan DEB Pts Estimated DEB Pts in Major EU* Markets Entering into distributor agreements for key ROW Over 300 DEB pts already markets st
Slide 6: Expanding and Repeat Prescriber Supports Continued Patient Penetration
Expanding and Repeat Prescriber Supports Continued Patient Penetration Rapid Penetration of U.S. Patient Pool Start Forms Split Start Form Split By DEB Subtype By HCP Setting 1,200 DDEB Identified U.S. DEB Patient Pool 25% Non-COE 53% RDEB 75% COE 35% 47% Patient Start Form Penetration To Date Over
Slide 7: Successfully Securing Broad Access and Reimbursement for VYJUVEK
Successfully Securing Broad Access and Reimbursement for VYJUVEK 228 Reimbursement Approvals To Date for Positive Coverage for Over 93% of Commercial VYJUVEK Patients and Medicaid Covered Lives Commercial Covered Lives Estimated 169M on Commercial Plans in U.S.* 7% 97% Positive Access 34% 59% Medica
Slide 8: High Demand for Home Dosing and Strong Patient Compliance
High Demand for Home Dosing and Strong Patient Compliance VYJUVEK Site of Care (February 2024) 2% Patient Compliance (2023) Home Treatment In Office Treatment 96% 98% - VYJUVEK Patient Ambassador Krystal | 8
Slide 9: Key Dynamics of VYJUVEK Launch
Key Dynamics of VYJUVEK Launch ▪ COE patient visits are complex and occurring at a steady pace ▪ Many prior COE DEB patients are now actively managed in the community ▪ Logistical aspects of scheduling an HCP and integrating into existing wound care routines - VYJUVEK Patient Ambassador Krystal | 9
Slide 10: VYJUVEK is Changing the Treatment Paradigm in DEB
VYJUVEK is Changing the Treatment Paradigm in DEB Krystal | 10
Slide 11: Validating the Breadth of Krystal's Redosable Gene Therapy Platform
Validating the Breadth of Krystal’s Redosable Gene Therapy Platform Indication Payload Preclinical Phase 1/2 Phase 3 Commercial Marketed Dystrophic epidermolysis bullosa (DEB) COL7A1 FDA Approved May 2023 in the U.S. KB105 Autosomal recessive congenital ichthyosis (ARCI) TGM1 KB104 Netherton syndrom
Slide 12: With FDA Approval of VYJUVEK, Development Focus Now on Ex-U.S. Markets
With FDA Approval of VYJUVEK, Development Focus Now on Ex-U.S. Markets Europe ▪ Marketing authorization application validated in November 2023 ▪ On track for 2H 2024 decision 2024 2025 Europe Japan Japan ▪ Received Orphan Drug Designation from PMDA in December 2023 ▪ Fully enrolled bridging trial an
Slide 13: 5 Clinical Trials in 2024
5 Clinical Trials in 2024 1 Ophthalmology Respiratory Oncology 1 3 ▪ First clinical data on B-VEC ▪ Initiated dosing in Cohort 2 of ▪ Dosed first patient with eyedrops published in the New KB407 Phase 1 trial CORAL-1 intratumoral KB707 in Phase 1 England Journal of Medicine trial OPAL-1 ▪ No severe
Slide 14: Fourth Quarter and Full Year 2023 Financial Highlights
Fourth Quarter and Full Year 2023 Financial Highlights Cash and investments: $594.1M as of December 31, 2023 ($ in millions) Three months ended Three months ended Year ended Year ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Product revenue, net $42.1M - $50.7M - Cost
Slide 15: Developing Genetic Medicines for Rare Diseases
Developing Genetic Medicines for Rare Diseases © Copyright 2024 Krystal Biotech, Inc. All rights reserved.